Qiming Venture Partners USA
VC Fund
Cambridge, United States
Qiming Venture Partners USA is a VC fund in Cambridge focused on Biotechnology and Health Care. Qiming Venture Partners USA, founded in 2017, is a healthcare venture capital firm and healthcare investor with deep technical expertise that allows them to identify tomorrow's innovations early and strong operational experience with a hands-on approach that makes us the investor of choice for early-stage biotech companies.Because of theirproven, hands-on approach to supporting CEOs and scaling operations, its partners are frequently sought after to serve on company boards. They are respected business and thought leaders.
- Total investments:
- 40
- Last investment:
- Lead investor:
- 20%
- Fund size:
- $260M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Qiming Venture Partners USA invests in
Stages Qiming Venture Partners USA invests in
Countries Qiming Venture Partners USA invests in
Round sizes
Round size
- Seed
- $6M–$55M
- Series A
- $14M–$92M
- Series B
- $36M–$116M
Investment Focus
Industry
- Biotechnology 17 (43%)
- Health Care 12 (30%)
- Pharmaceutical 7 (18%)
- Medical 6 (15%)
- Biopharma 5 (13%)
Stage
- Series A 12 (30%)
- Series B 12 (30%)
- Seed 3 (8%)
- Series C 3 (8%)
- Post-IPO Equity 3 (8%)
Country
- United States 17 (43%)
- Canada 2 (5%)
- China 1 (3%)
- Latvia 1 (3%)
- Hong Kong 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Tenpoint Therapeutics
|
Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | $85M / Series B / Jan 28, 2026 | |
Rhino Federated Computing
|
Rhino Federated Computing solves one of the biggest challenges in AI: seamlessly connecting siloed data through federated computing. The Rhino Federated Computing Platform (RhinoFCP) serves as the ‘data collaboration tech stack’, extending from providing computing resources to data preparation & discoverability, to model development &monitoring — all in a secure, privacy-preserving environment. To do this, Rhino FCP offers flexible architecture (multi-cloud and on-prem hardware), end-to-end data management workflows (multimodal data, schema definition, harmonization, and visualization), privacy enhancing technologies (e.g., differential privacy), and allows for the secure deployment of custom code & 3rd party applications via persistent data pipelines. Rhino is trusted by >60 leading organizations worldwide — including 14 of 20 of Newsweek’s ‘Best Smart Hospitals’ and top 20 global biopharma companies — and is leveraging this foundation for financial services, ecommerce, and beyond. The company is headquartered in Boston, with an R&D center in Tel Aviv. | $11.3M / Series A / Jan 27, 2026 | |
Dualitas Therapeutics
|
Dualitas Therapeutics is leading the way in bispecific antibody treatments for inflammatory and immunological (I&I) disorders and other conditions. With a growing collection of innovative cell surface proximity engagers and our in-house DualScreen™ discovery engine, our pipeline | $65M / Series A / Sep 16, 2025 | |
Renasant Bio
|
Renasant Bio is a biopharmaceutical company pioneering disease-modifying oral small molecule treatments. | $54.5M / Seed / Jul 10, 2025 | |
|
Rhino Federated Computing
|
Rhino Federated Computing solves one of the biggest challenges in AI: seamlessly connecting siloed data through federated computing. The Rhino Federated Computing Platform (RhinoFCP) serves as the ‘data collaboration tech stack’, extending from providing computing resources to data preparation & discoverability, to model development &monitoring — all in a secure, privacy-preserving environment. To do this, Rhino FCP offers flexible architecture (multi-cloud and on-prem hardware), end-to-end data management workflows (multimodal data, schema definition, harmonization, and visualization), privacy enhancing technologies (e.g., differential privacy), and allows for the secure deployment of custom code & 3rd party applications via persistent data pipelines. Rhino is trusted by >60 leading organizations worldwide — including 14 of 20 of Newsweek’s ‘Best Smart Hospitals’ and top 20 global biopharma companies — and is leveraging this foundation for financial services, ecommerce, and beyond. The company is headquartered in Boston, with an R&D center in Tel Aviv. | $15M / Series A / May 22, 2025 | |
Auron Therapeutics
|
Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancerto normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples. | $27.3M / Series B / Feb 04, 2025 | |
Umoja Biopharma
|
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer. | $100M / Series C / Jan 14, 2025 | |
|
Tenpoint Therapeutics
|
Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics. | Venture - Series Unknown / Dec 11, 2024 | |
Evermore
|
Soda Health is a healthcare technology company focused on building solutions that eliminate health inequities and create a healthier America. | $54.2M / Series B / Dec 03, 2024 | |
Jasper Therapeutics
|
Jasper is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. Jasper’s lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem celltransplant. | $50M / Post-IPO Equity / Feb 06, 2024 | |
| See all 40 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Qiming Venture Partners USA invest in?
Qiming Venture Partners USA invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series A and Series B stage. Most of the 40 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Qiming Venture Partners USA's check size?
Qiming Venture Partners USA typically joins rounds of $6M–$55M at Seed, $14M–$92M at Series A and $36M–$116M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Qiming Venture Partners USA participates in.
When did Qiming Venture Partners USA last invest?
The most recent investment recorded for Qiming Venture Partners USA closed in Jan 2026. Shizune tracks 40 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
